

## pSMPUW-IRES-Puro Lentiviral Expression Vector

---

**CATALOG NUMBER:** VPK-215

**STORAGE:** -20°C

**QUANTITY AND CONCENTRATION:** 10 µg at 0.25 µg/µL in TE

### **Background**

Lentivirus vector based on the human immunodeficiency virus-1 (HIV-1) has become a promising vector for gene transfer studies. The advantageous feature of lentivirus vector is the ability of gene transfer and integration into dividing and non-dividing cells. The pseudotyped envelope with vesicular stomatitis virus envelope G (VSV-G) protein broadens the target cell range. Lentiviral vectors have been shown to deliver genes to neurons, lymphocytes and macrophages, cell types that previous retrovirus vectors could not be used. Lentiviral vectors have also proven to be effective in transducing brain, liver, muscle, and retina *in vivo* without toxicity or immune responses. Recently, the lentivirus system is widely used to integrate siRNA efficiently in a wide variety of cell lines and primary cells both *in vitro* and *in vivo*.


Lentivirus particles are produced from 293T cells through transient transfection of plasmids that encode for the components of the virion. Due to safety concerns regarding the infectious nature of HIV-1, recent lentiviral packaging systems have separated the viral components into 3 or 4 plasmids. However, these systems still present a small chance of generating replication-competent lentivirus upon recombination. In addition, most commercial lentiviral packaging systems provide plasmids containing the viral structure proteins in a premixed formulation, making it nearly impossible to optimize the ratio of the various plasmids for your particular experiment and host cell.

pSMPUW-IRES-Puro Lentiviral Expression Vector contains EF-1 $\alpha$  promoter ahead of the multiple cloning sites, followed by an IRES and puromycin resistant gene (Figure 1).

### **Related Products**

1. VPK-206: ViraSafe™ Lentiviral Packaging System, Pantropic
2. VPK-107: QuickTiter™ Lentivirus Titer Kit (Lentivirus-Associated HIV p24)
3. LTV-200: ViraDuctin™ Lentivirus Transduction Kit

## Unique Elements of the pSMPUW Universal Lentivirus Expression Vector




Element	Name	Benefits compared to other 3 <sup>rd</sup> Generation Systems
<b>ELEMENTS ADDED</b>		
	Central Polypurine Tract	<ul style="list-style-type: none"> <li>Increased gene expression levels</li> </ul>
	Hybrid 3' LTR Poly(A)	<ul style="list-style-type: none"> <li>Increased safety: prevents read-through transcription</li> <li>Increased viral titer: vector transcript more stable in packaging cells</li> </ul>
	WPRE	<ul style="list-style-type: none"> <li>Increased viral titer</li> </ul>
<b>ELEMENTS DELETED</b>		
	Gag sequence	<ul style="list-style-type: none"> <li>Increased safety: reduces sequence homology</li> </ul>
	Rev-Responsive Element	<ul style="list-style-type: none"> <li>Increased safety: reduces sequence homology</li> </ul>

### Safety Considerations

Remember that you will be working with samples containing infectious virus. Follow the recommended NIH guidelines for all materials containing BSL-2 organisms. The ViraSafe™ Universal Lentiviral Expression System is designed to minimize the chance of generating replication-competent lentivirus, but precautions should still be taken to avoid direct contact with viral supernatants.

### pSMPUW-IRES-Puro Vector



MCS: AACGTTTCGGCCGGCCAGATATCTCCCTTCGGACCAAGGGTCATTAATTAAGAATTCCGCCCTCT  
 FseI EcoRV AhdI PacI EcoRI

**Figure 1:** pSMPUW-IRES-Puro Lentiviral Expression Vector (6237 bp, Kanamycin-resistant). EcoRI and XhoI Digestion: 1687 bp + 4550 bp.

*Note: Bacterial culture of pSMPUW vectors should be done in medium containing 10 µg/mL Kanamycin. For maximal plasmid yield and quality, we recommend Stbl3 endoA1+ competent cells (Invitrogen) and*

treatment with alkaline proteinase (Promega #A1441 or Sigma #P8038) for 4-5 min using 10 units of proteinase per mL of bacterial lysate before adding neutralization solution.

## **Lentivirus Production**

1. One day before transfection, plate sufficient 293T cells or 293LTV cells (Cat. #LTV-100) to achieve 70-80% confluence on the day of transfection.
2. Transfect cells by Calcium Phosphate or other transfection reagents.

*Note: We suggest transfecting cells with FuGENE® Transfection Reagent (Roche Applied Science) or Lipofectamine™ Plus (Invitrogen). We recommend the ratio of vectors at 3:1:1:1 (pSMPUW:pCMV-VSV-G:pRSV-REV:pCgpV).*

3. Harvest lentiviral supernatant 36-72 hours after transfection. Supernatant can be harvested 2 or 3 times, every 12 hours. Keep it at 4°C over the collecting period.
4. Pool the collected supernatants, centrifuge 5 minutes at 1500 rpm to remove cell debris and filtrate on 0.22 µm.
5. Supernatants can be used directly or purified/concentrated if needed. For long term storage, store supernatant at -80°C in aliquots.

## **Post-Packaging Considerations**

Packaging your lentivirus is only the first step to ensuring successful expression of your gene. The following steps should be considered prior to infection of your host cell:

1. **Concentration and purification of your lentivirus:** Because of the latent nature of lentivirus, it is imperative that your virus be highly concentrated before infecting your host cell. Also, impurities from your viral supernatant can decrease the efficiency of infection.
2. **Measure the titer of your lentivirus:** This is an important step to ensure consistent viral transduction into your host cell. However, QPCR or stable clone counting can take as much as 1-2 weeks to perform. Traditional p24 ELISA kits can greatly overestimate your lentiviral titer. Our advanced p24 ELISA, QuickTiter™ Lentivirus Titer Kit (Catalog # VPK-107), uses exclusive technology that eliminates free p24 from your supernatant, giving you much more accurate lentiviral titers. Results are obtained in 6-18 hours.
3. **Use transduction reagents to increase infection efficiency:** Many cells are difficult to infect with lentivirus, and without supplemental reagents transduction efficiencies can be low. Reagents such as Polybrene® can help, but are often insufficient. Cell Biolabs' proprietary reagents in our ViraDuctin™ Lentivirus Transduction Kit (Catalog # LTV-200) form a super-complex with your virus to increase transduction efficiencies by promoting virus and cell interaction.

**pSMPUW-IRES-Puro Plasmid Sequence**

**Pink:** 5' CMV/LTR, ψ, cPPT

**Blue:** EF-1

**Purple:** MCS

**Red:** IRES

**Green:** Puro

**Brown:** WPRE

**Orange:** 3' LTR

**Blue:** Kanamycin Resistance gene

ACTAGTCGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTTGAC  
GTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGCACTTTCATTGACGTCAATGGTGGAGTATTACGGTAACTGCCACTTGGCAGTACATCAAGTG  
TATCATATGCCAAGTACGCCCTATTGACGTCAATGACGTAATGGCCCGCTGCAATATGGCCAGTACATGACCTTATGGGACTTTCCTACTTGGGAGTACA  
TCTACGTATTAGTCACTCGCTATTACCATGGTATGCGGTTTTGGCAGTACATCAATGGCGTGGATAGCGGTTGACTCACGGGATTTCCAAGTCTCCACCCCAT  
TGACGTCAATGGGAGTTTTGTTTTGCCACAAAATCAACGGGACTTTCAAAATGTCGTAACAACCTCCGCCCATTTGACGCAAAATGGGCGTAGGCGTGTACGGTGG  
GAGTCTATATAAGCAGAGCTGGTATTAGTGAACCGGCTCTCTGGTGTAGACAGATTTGAGCCTGGGAGCTCTCTGGCTAATAGGAAACCCACTGCTTAAGCCT  
CAATAAAGCTTGCCTTGGCTTCAAGTAGTGTCCCGCTCTGTTGTGTGACTTGTTAACTAGCTTACTGACCGAGAGCCCTTGAATAAGGCCGGTGTGCGTTGTCTATATGT  
GCAGTGGCGCCGACAGGGACCTGAAAGCGAAAGGGAACAGAGGAGCTCTCTCGACGAGGACTCGGCTTGTGAAGCGCGCACGGCAAGAGGCGAGGGGGCGG  
CGACTGCAGAGTACGCCAAAATTTGACTAGCGGAGGCTAGAAGGAGAGATGGGTGCGAGAGCGTCACTTAAAGCGGGGAAAATAGCGGCCGCCACAATTTT  
AAAAGAAAAGGGGGATGGGGGTCAGTGCAGGGGAAGAATAGTACATAAATAGCAACAGACATAACAATAAAGAATTACAAAACAAATTACAAAATTC  
AAATTTTCGCGGATTCGCTCCCGCTCACCACCCCAACCCGCCGACCGGAGCTGAGAGTAATTCATACAAAAGGACTGCCCTGCCTGGGGAATCCC  
AGGGACCGCTGTTAACTCCCACTAACGTAGAACCAGAGATCGTGGCTTCCCGCCCTCACCAGCGCTCTCGTCACTACTGAGGTGGAGAAGAGCATGCGT  
GAGGTCCGCTGCCGCTCACTGGGAGAGCGCACATCGCCACAGTCCCGGAGAGTTGGGGGAGGGGTCCGCCAATGAACCGTGCCTAGAGAAAGGTGGCGCG  
GGTAACTGGGAAAGTGTGCTGTACTGGCTCCGCTTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTGTGCGGTGAACGTTCCGCGCCAG  
TATCTCCCTTCGGACCAAGGGTCATTAATTAAGAATTCCGCCCTCTCCCTAACCTTACTGACCGGAGCCCTTGAATAAGGCCGGTGTGCGTTGTCTATATGT  
TATTTTCCACCATTATGGCGCTTTTTGGCAATGTGAGGGCCGGAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTCCCTCTCGCAAAGGAAT  
GCAAGGTCTGTTGAATGTGTGAAGGAAGCAGTTCTCTGGAAGCTTCTGAAGCAACAACAGCTCTGTAGCGACCTTTGCAGGCGAGCGGAACCCCAACTGGC  
GACAGGTCTCTCGCGCAAAAAGCCAGTGTATAAGATACACCTGCAAGGCGGCACAACCCAGTCCACGTTGTGAGTTGGATAGTTGTGGAAGAGTCAAAAT  
GGCTCTCCTCAAGCGTATTCAACAAGGGCTGAAGGATGCCAGAGTACCCCATTTGATGGATCTGATCTGGGCGCTCGGTGCACATGCTTACATGTGTTTA  
GTCGAGGTTAAAAAACGCTAGGCCCGCCGAAACCAGGGGACGTGGTTTTCTTTGAAAAACACGATGATAATATGGCCACAACCATTGGTTACCGAGTACAAGCC  
CACGTTGCGCTTCGCCACCCGCGCAGCAGCTCCCAAGGGCCGTCAGCACCTCGCCGCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTGCATCCGGACCGC  
CACATCGAGCGGGTACCCAGCTGCAAGAATCTTCTCAGCGCGTTCGGGTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCGCGGTGGCGGTTGGA  
CCACCGGAGAGCGTGAAGCGGGGGCGGTGTTTCGCGGAGATCGCCGCGCATGGCCGAGTTGAGCGGTTCGCCGCTGGCCGCGCAGCAACAGATGGAAGCGCT  
CCTGGCGCGCACCCGCCAAGGAGCCCGCTGGTTCTGCGCACCGTTCGGGCTCGCCCGACCCAGGGGCAAGGTCTGGGAGCGCGCTGCTCCCGGA  
GTGGAGCGCGCGAGCGCGCGGGTGCCTTCCTGGAGACCTCGCGCGCCGCAACCTCCCTTCACGAGCGGCTCGGCTTCACCGTCAACCGCGACGCTG  
AGTTCGCGCAAGCCCGCACCTGGTGCATGACCCGCAAGCCGGTGCCTGAGTCGACAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCT  
TAATATGTTGGTCCCTTTTACGCTATGTGGATACGCTGCTTAAATGCTTTGATATCATGCTATTGCTTCCCGGTATGGCTTCCCGTATGGCTTTTCTCCTCTGTATAAAATCC  
TGTTGTGTCTCTTTATGAGGAGTTGTGGCCGTTGTGAGGCAACGTGGCGTGGTGTGCACTGTGTTGCTGACGCAACCCCACTGGTTGGGCAATTGCCACCA  
CCTGTCAGCTCCTTCCGGGACTTTCGCTTCCCGCTCCTATTGCCAGCGGGAACCTATCGCCGCTGCCTTCCCGCTGCTGGACAGGGGCTCGGCTGTGGG  
CACTGACAATTCGTTGTTGTGCGGGAAATCATGCTCTTCTTGGCTGCTCGCTGTTGCCACTGGATTCTGCGCGGAGCTCCTTCTGTACTGCTCCCT  
TCGGCTCAATCCAGCAGGACTTCTCCCGCGGCTGCTCCCGCTCGCGGCTCTCGGCTTTCGCTTCCCGCTCAGACGAGTCCGATCTCCCTTTGGG  
CCGCTCCCGCTTAGTACTGGTACCTTTAAGACCAATGACTTACAAGGAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGACTGGAAGGGCTAATTC  
ACTCCAACGAAAGACAAGATTCCGGAATTTATTTGTGAAATTTGTGATGTATTGCTTTATTTGTAACCAGGTCAGCTGCTTTTTCGCTGACTGGGTCTCTG  
GTTAGACAGATCTGAGCTGGAGCTCTCTGGTAACTAGGAAACCCACTGCTTAAAGCTCAATAAAGCTTGCCTGAGTGTCAAGTAGTGTGTGGCCGCTG  
GTTGAGACTCTGGTAACTAGGACTCCCTCAGACCTTTTAGCTCAGTGTGGAATCTCAGCACTAGAGTATGCAAAGCATGCAATGATGAGTGTGAGCAACCA  
GGTGTGGAAGTCCCAAGGCTCCCAAGCAGCAGAGATGCAAAGCATGCATCTCAATAGTACGCAACCATAGTCCCGCCCTAATCCGCCCATCCCGCCCT  
AATCCGCCAGTTCGCCCATTTCCGCCCATGGCTGACTAATTTTTTTTATTATGCAAGGCGGAGCCGCTCGGCTCTGAGCTATTCCAGAAGTAGTGA  
GAGGCTTTTTTGGAGGCTAGGCTAGAGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGTGTTTTAAAAAACCCTCCACACCTCCCGCTGAACCTGAA  
ACATAAATGAATGCAATTTGTTGTTAACTTTGTTTATGTCAGTTATAATGGTACAAAATAAAGCAATAGCATCAAAAATAAAGCATTTTTTTTCA  
CTGCAATCTAGTTGTGGTTTTGTCCAACTCATCAATGTATCTTATCATGTCGTAGCCGGGTTTTTTTTTCTTAGGCTTCTCCGCTTCTCCGCTCACTGACTC  
GCTGCGCTCGGTCGTTCCGTCGCGGAGCGGTATCAGCTCACTCAAAGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGAGGAAAGAACATGTGAGCA  
AAAGGCCAGCAAAAAGGCGAGAACCGTAAAAGGCCCGCTTGGCTGGCCTTTTCCATAGGCTCCGCCCCCTGACGAGCATCAAAAATCGACGCTCAAGTCA  
GGTGGCAAAACCCGACGAGACTATAAAGATACAGGCTTTCCTCCGTTGAAGCTCCCTCGTGGCTTCCGCTTCCGCTCAGACGAGTCCGATCTCCCTTTGG  
CTTCTCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCTGTAGTATCTCAGTTCCGTTGAGGCTGTTCCGCTCCAAAGCTGGGCTGTGTGCACGAACCCCC  
GTTACGCCGACCGCTGCGCTTATCCGGTAACTATCGTCTTGTAGTCCAACCCGTAAGACAGACTTATCGCCACTGGCAGCAGCCACTGGTAAAGGATAGCA  
GAGCGAGGTATGTAGCGGCTGACAGAGTTCTTGAAGTGGTGGCCTAACACTAGGCTACACTAGAAGAACAGTATTGTTGATCTGCGCTCTGCTGAAGCCAGTTAC  
CTTCGGAATAAGAGTTGGTACTTTGATCCGCAAAACAACACCCGCTGGTAGCGGTTTTTTTTTGTGCAAGCAGCAGATTACCGCGAGAAAAGGATCT  
CAAGAAGATCCTTTGATCTTTCTACGGGTCTGACGCTCAGTGGAAACGAAATCAACGTTAAAGGATTTGGTCAATGAGATTAACAAGGATCTTACCTAGA  
TCCTTTTAAATTAATAAGTTTTAAATCAATCAAAAGTATATAGTAAACTTGGTCTGACAGTTACCAATGCTTAACTAGTGGACCTATCTCAGCGAT  
CTGCTATTTTCGTTCACTAGTTGCTGACTCTGCGAGTCAAAAAGGCTCCAAAAGGAGGCTTTAATTTGATCGGTTGGGCCCTTAGAAAACTCATC  
GAGCATCAATGAACCTCAATTTATCATCAGGATTAATCAATACCATTTTTTGAAGACCGGTTTTCTGTAATGAAGGAGAAAATCACCAGGCACTTCCAT  
AGGATGGCAAGATCTGGTATCGGTTCCGACTTCGACCTGCTCAACATAACAACTAATTAATTTCCCTCGTCAAAAATAAGGTTTACAGTGAGAAATC  
CATGAGTGCAGCTGAATCCGGTGAAGTGGCAAAAGCTTATGCATTTCTTCCAGACTTGTCAACAGGCGAGCCATTACGCTCGTCATCAAAATCACTCGCATC  
AACCAAAACCGTATTCACTCGTGTATGCGCTGAGCGAGACGAATACCGCATGCTGTTAAAGGACAATTAACAACAGGAATCGAATCAACCGGCGCAGGAAC  
ACTGCCAGCGCATCAACAATTAATTTCACTGAATCAGGATATCTTCTAATACCTGGAATGCTGTTTTCCCGGGATCGCAGTGGTGAATCACTCATCAG  
GAGTCGGATAAAAATGCTTGTATGGTGGGAAGGCATAAATTTCCGTCAGCCAGTTTAGTCTGACCATCTCTGTAACATCACTGGCAAGCTACCTTTGCCATG



TTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTGCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCA  
TCCATGTTGGAATTTAATCGCGGCCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCAT AACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTTC  
ATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGTTTAAACAAATAGTCAAAAGCCTCCGGCG

## **References**

1. Chen, M. et al. (2002). *Nature Genetics* **32(4)**: 670-675.
2. Naldini, L., U. Blomer, P. Gally, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono (1996) *Science* **272**:263-267.
3. Verma, I. M., and N. Somia (1997) *Nature* **389**:239-242
4. Kahl C. A., Marsh J., Fyffe J., Sanders D. A., and K. Cornetta (2004) *J Virol.* **78**:1421-30.
5. White S. M., Renda M., Nam N. Y., Klimatcheva E., Zhu Y., Fisk J., Halterman M., Rimel B. J., Federoff H., Pandya S., Rosenblatt J. D., and V. Planelles (1999) *J Virol.* **73**:2832-40.
6. Kafri T., van Praag H., Ouyang L., Gage F. H., and I. M. Verma (1999) *J Virol.* **73**:576-84.

## **Recent Product Citations**

1. Zhao, G. et al. (2020). NLRX1 knockout aggravates lipopolysaccharide (LPS)-induced heart injury and attenuates the anti-LPS cardioprotective effect of CYP2J2/11,12-EET by enhancing activation of NF- $\kappa$ B and NLRP3 inflammasome. *Eur J Pharmacol.* doi: 10.1016/j.ejphar.2020.173276.
2. Zhang, J. et al. (2018). Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response. *Sci Rep.* **8(1)**:2373. doi: 10.1038/s41598-018-20779-2.
3. Koso, H. et al. (2016). Identification of RNA-binding protein LARP4B as a tumor suppressor in glioma. *Cancer Res.* doi:10.1158/0008-5472.CAN-15-2308.
4. Zhang, S. et al. (2013). A Novel Function of CRL4Cdt2: regulation of the subunit structure of DNA POLYMERASE  $\{\delta\}$  in response to DNA damage and during the S phase. *J. Biol. Chem.* **288**:29550-29561.

## **Notice to Purchaser**

This product is sold for research and development purposes only and is not to be incorporated into products for resale without written permission from Cell Biolabs. The patented technology is covered by a license from CHLA and University of Southern California. By the use of this product you accept the terms and conditions of all applicable Limited Use Label Licenses. You may contact our Business Development department at [busdev@cellbiolabs.com](mailto:busdev@cellbiolabs.com) for information on sublicensing this technology.

## **Warranty**

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

***This product is for RESEARCH USE ONLY; not for use in diagnostic procedures.***

## **Contact Information**

Cell Biolabs, Inc.  
5628 Copley Drive  
San Diego, CA 92111  
Worldwide: +1 858-271-6500  
USA Toll-Free: 1-888-CBL-0505  
E-mail: [tech@cellbiolabs.com](mailto:tech@cellbiolabs.com)  
[www.cellbiolabs.com](http://www.cellbiolabs.com)

©2009-2022: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.